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Abstract: The aim of the present work was to widen the application of an 
in-house developed fast, flexible and sensitive high performance liquid chro-
matography (HPLC) method to the assessment of cefotaxime sodium from 
aqueous samples. The method was applied to establish the release profile of 
cefotaxime sodium immobilised in MCM-41 nanoparticles using pH-controlled 
release in an aqueous medium. The analytical method proved to be sensitive, 
repeatable (RSD < 1.5 %) and reproducible (RSD < 1 %) in the studied concen-
tration range (0.01–10 μg·mL-1). The limit of detection and limit of quantifi-
cation were 0.036 and 0.12 μg·mL-1, respectively, suitable for the analysis of 
the release of a single active ingredient, and the analysis time was short (10 
min). 
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INTRODUCTION 
Cefotaxime sodium (Fig. 1) is a third generation cephalosporin antibiotic 
that has wide clinical applications for treatment of infections of the respiratory 
tract, gynaecologic, skin, bone and joint, urinary tract, septicaemia, and docu-
mented or suspected meningitis.1 
For the analysis of cefotaxime sodium, several methods have been employed: 
electrochemical (cyclic voltammetry, square wave voltammetry),2–4 spectrofluo-
rimetric and chemiluminescent,5,6 and high performance liquid chromatographic 
methods.7,8 Some performance characteristics of methods applied in the deter-
mination cefotaxime or its metabolites are presented in Table I. 
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The aim of this study was the development and application of a sensitive 
chromatographic method with dual detection (diode array and mass spectrometry, 
HPLC-DAD–MS) for the determination of cefotaxime immobilized on the meso-
porous material MCM-41, which is an ordered mesoporous silicate that displays 
cylindrical mesopores having a unit cell size of 4.6–4.8 nm. In recent years, it is 
the most used support for the controlled release of drugs.9–14 Cefotaxime sodium 
was used as the model drug, a dual detection mode being chosen to ensure a 
better selectivity of the method. According to the British Pharmacopoeia (2009), 
cefotaxime sodium is an easily degradable antibiotic. Any detectable impurities 
might affect the efficacy of the bioactive compound (e.g., cefotaxime dimers if 
present at a sufficient level. Therefore, the employment of MS analysis was just-
ified in order to provide exact information on the nature and form in which the 
analyte occurred. 
 
Fig. 1. Chemical structure of cefotaxime sodium. 
TABLE I. Comparison between the performance characteristics of previous methods applied 
in cefotaxime determination 
Analyte Sample  matrix Method  LOD / µg mL-1 Reference 
Cefotaxime, desacetylcefotaxime,  Ocular aqueous 
humour 
HPLC 0.08  7 
Cefotaxime, desacetylcefotaxime,  Plasma  HPLC–UV 0.31  7 
Cefotaxime Plasma  HPLC–UV 1.0  8 
EXPERIMENTAL 
Chemicals and reagents 
The cefotaxime sodium standard (MW 477.5) used in this study was purchased from 
Sigma–Aldrich (Steinheim, Germany). HPLC grade methanol was from Merck (Darmstadt, 
Germany). All stock solutions and samples were prepared with ultrapure water. 
Instrumentation and procedure 
The HPLC analysis was realised on a Shimadzu HPLC system (SCL-10A VP, Kyoto, 
Japan), consisting of a degasser (DGU-20A5), two pumps (LC-10AD VP) for the delivery of 
the mobile phase, a thermostatic system (CTO-10AS), and a system controller (SCL – 10A 
VP). Detection was achieved using a diode array detector (SPD – M20A). A C18 analytical 
column (150 mm×4.6 mm, 5 μm i.d., Fortis) was used in the analysis. The oven temperature 
was set at 25 °C. A CyberScan PCD6500 pH/ion/conductivity/DO meter from Eutech Instru-
ments was used for pH measurements of the mobile phase. 
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A Shimadzu mass spectrometer, model 2010, was employed, using an electro-spray 
ionization interface, in positive mode. The tuning of the detector was accomplished prior each 
set of determinations, using an appropriate tuning mixture. The detector settings were ESI (+) 
CDL temperature 250 °C, nebulizing gas flow 1.5 L min-1, heat block 200 °C.  
Chromatographic procedure. The chromatographic analysis was performed in isocratic 
mode, using as mobile phase a mixture of methanol and water (30:70, V/V), adjusted at pH 4.0 
with acetic acid. The flow rate was 0.8 mL min-1. The chromatographic conditions were as 
follows: the injection volume was 20 μL, column temperature 25 °C, detection was performed 
at 235 nm and the time of analysis was 10 minutes. 
The calibration curve for HPLC-DAD analysis was obtained in a range between 0.01 to 
10 μg·mL-1, using the average area from triplicate analysis. 
Preparation of the standard solution 
A stock standard solution of cefotaxime sodium (2000 μg·mL-1) was prepared in 
ultrapure water. The solution was kept in the refrigerator to prevent degradation. Working 
standard solutions were freshly prepared before analysis in water at concentrations ranging 
from 0.01 to 10 μg·mL-1. Before use, the solutions were filtered through a 0.20 µm filter. 
Drug immobilisation 
Cefotaxime sodium was immobilised in MCM-41by mixing 0.32 g of active substance 
with 0.07 g of MCM-41 in 10 mL of ultrapure water. The mixture was left to settle for 24 h, 
filtered and dried in a vacuum desiccator for 24 h. The amount of cefotaxime immobilised was 
9.19 % (0.098 g, calculated from the difference in initial concentration of cefotaxime solution 
and final concentration of the supernatant (determined by HPLC). 
Conditions of release 
The release profile for cefotaxime immobilized in MCM-41 was adjusted considering the 
BP releasing tests appropriate for β-lactam antibiotics: 20 mg of the composite (cefotaxime 
sodium and MCM-41) was mixed with 20 mL of phosphate buffer (to simulate body fluid) at 
pH 4.80 and kept at a constant mixing rate of 200 rpm. The total release time was 6 h. 
Samples of 1 mL were collected, centrifuged for 10 min at 9000 rpm, two times, and after-
wards the supernatants were filtered through a 0.20 μm PTCE membrane and injected into the 
HPLC system for analysis. 
RESULTS AND DISCUSSIONS 
In the present work, the development and partial validation (in terms of 
linearity, limit of detection, limit of quantification, repeatability and reproduci-
bility) of the HPLC-DAD–MS method was performed and the releasing process 
of immobilized cefotaxime sodium in mesoporous supports was studied. Diffe-
rent mobile phase compositions were tested and it was found that a mobile phase 
of methanol:water 30:70 (V/V) (pH 4.00, buffered with acetic acid) resulted in an 
acceptable resolution (retention times), peak shape (Gaussian) and time of anal-
ysis at a column temperature of 25 °C for the studied antibiotic. Various station-
ary phases were tested, a Fortis C18 analytical column was successfully used 
being more efficient than a classical silica-based packing. The detection wave-
length was 235 nm. 
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The peak specific for cefotaxime sodium was characterized by a retention 
time of 4.6 min. A typical chromatogram for the standard compound, obtained 
under the described optimal experimental conditions, is shown in Fig. 2. The 
chromatographic peak corresponding to the studied drug eluted at a retention 
time of 4.6 min and presented a well-shaped Gaussian form, separated from the 
solvent front. A total analysis time of around 10 min was employed to ensure 
adequate column equilibration between two subsequent analyses. No significant 
interfering chromatographic peaks were observed in the HPLC chromatograms 
during the analysis of cefotaxime sodium samples released from the support 
nanoparticles. No interferences from the sample solvent or from impurities were 
observed at the employed detection wavelength. 
 
Fig. 2. HPLC-DAD chromatogram for cefotaxime sodium standard (1 μg·mL-1). 
Partial validation of the method 
The linear response ranged from 0.01 to 10 μg·mL–1. The LOD and LOQ 
values were calculated from the slope and the standard deviation of a blank 
signal. For repeatability and reproducibility, every level of concentration was 
injected three times into the chromatographic system and three injections from 
three different solutions with the same concentration of standard working 
solution (0.5 μg·mL–1) were analysed. All results are presented in Table II. 
The presence of the studied compound was confirmed by HPLC-DAD–MS 
analysis. The previously developed and validated method was adjusted to the MS 
conditions. The column and the mobile phase were the same as those used for the 
HPLC-DAD analysis. The only adjustment was in the flow rate (0.2 mL min–1), 
with an analysis time of 10 minutes and injection volume of 10 μL. 
The MS spectrum of cefotaxime sodium is given in Fig. 3. 
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TABLE II. Several performance characteristics of the HPLC-DAD method applied to cefo-
taxime sodium determination 
Parameter  Reference solution, cefotaxime sodium 
Linearity range, μg·mL-1 0.05–10 
Retention time, min  4.6 
Slope 1443423.72 
Intercept 32855.62 
Correlation coefficient  0.9988 
LOD / μg·mL-1 0.036
LOQ / μg·mL-1 0.12
Repeatability, RSD / %  1.28 
Reproducibility, RSD / %  0.70 
 
Fig. 3. MS (ESI+) spectrum of cefotaxime sodium. 
Application of the HPLC method to the release of cefotaxime sodium 
One of the applications of HPLC method is the determination of antibiotics 
in pharmaceuticals. For this purpose, the release of cefotaxime sodium immo-
bilised in MCM-41 nanoparticles was studied.  
The release profile of the biologically active compound from the MCM-41 
composite and the corresponding chromatograms are given in Figs. 4 and 5, res-
pectively. 
The released cephalosporin was identified using the retention time and the 
MS spectrum, since the obtained coefficient of variation was appropriate. The 
observed retention time (4.6 min) enabled the rapid determination of the analyte. 
The method provides better limits of detection (LOD) and quantification (LOQ) 
than those of other reported methods (Table I); even compared to those of a 
method able to discriminate between cefotaxime enantiomers since Wang et al. 
reported the separation and determination of cefotaxime enantiomers in injec-
tions by capillary zone electrophoresis with an LOD of 0.5 µg mL–1.15 
Thus, the method was successfully applied to in vitro release of cefotaxime 
sodium into an aqueous medium of controlled pH. 
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Fig. 4. The release profile of cefotaxime sodium (as adsorbed mass) immobilised in 
mesoporous silica MCM-41. 
 
Fig. 5. HPLC-DAD chromatogram for cefotaxime sodium sample at different release times 
(a – 20 min, b – 50 min, c – 90 min, d – 120 min, e – 180 min). 
CONCLUSIONS 
An HPLC-DAD method was developed and partially validated, in terms of 
linearity, limit of detection, limit of quantification, repeatability and reproduci-
bility to determine cefotaxime sodium and then applied to the controlled release 
of the drug immobilised in mesoporous MCM-41 nanoparticles. 
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The main improvement of the proposed method with respect to published 
methods is the increase in sensitivity (with two magnitude folds) of the LOD and 
LOQ and also the relatively low cost of the chemicals used. 
The proposed chromatographic method is a simple (uses common solvents, 
and there is no necessity for a particular preparation of the samples, standards or 
mobile phase) and rapid procedure (the total analysis time is only 10 min and the 
retention time is short) for the determination of cefotaxime sodium in aqueous 
samples. Moreover, its application in establishing the release profiles was proved. 
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ИЗВОД 
ХРОМАТОГРАФСКА АНАЛИЗА ИМОБИЛИСАНОГ ЦЕФОТАКСИМА 
DANIELA STIRBET
1, SIMONA-CARMEN LITESCU
2 и GABRIEL-LUCIAN RADU
1 
1Department of Analytical Chemistry and Environmental Engineering, Faculty of Applied Chemistry and 
Material Sciences, “Politehnica” University of Bucharest,1–7 Gheorghe Polizu, District 1, Bucharest-011061, 
Romania и 2Centre of Bioanalysis, National Institute of Biological Sciences, Bucharest, 296 Splaiul 
Independentei, District 6, Bucharest-060031, Romania 
Циљ овог рада је проширење примене једне, лабораторијски већ развијене, брзе, 
флексибилне  и  осетљиве  методе  високоефикасне  течне  хроматографије (HPLC), за 
одређивње  натријум-цефотаксима  у  воденим  узорцима.  Метода  је  примењена  ради 
одређивања  профила  ослобађања  натријум-цефотаксима,  имобилисаног  на MCM-41 
наночестицама, применом pH контролисаног ослобађања у воденој средини. Доказано је 
да је метода осетљива, са добром поновљивошћу (RSD < 1,5 %) и репродуктивношћу 
(RSD < 1 %) у испитиваном концентрационом опсегу (0,01–10 μg·mL-1), са границама 
детекције  и  квантификације 0,036, односно 0.12 μg·mL-1,  и  погодна  за  анализу  осло-
бађања појединачних активних компоненти са кратким временом анализе (10 min). 
(Примљено 21. августа 2013, ревидирано и прихваћено 22. јануара 2014) 
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